Abstract
Current tuberculosis (TB) treatment is based on a combination of drugs that were developed mostly in the central decades of the last century. Cure rates are high for drug sensitive strains of Mycobacterium tuberculosis (M. tb) when the recommended complex and lengthy treatment protocols are adhered to. However the difficulty in correctly prescribing and adhering to these protocols, the emergence of M. tb strains resistant to multiple drugs, and drug-drug interactions that interfere with optimal treatment of HIV and TB coinfected patients have generated a pressing need for improved TB therapies. Together with the ominous global burden of TB, these shortcomings of current treatment have contributed to a renewed interest in the development of improved drugs and protocols for the treatment of tuberculosis. This article highlights hurdles related to the optimized use of existing drugs and challenges related to the development of novel, improved products, focusing in particular on aspects inherent in TB drug clinical development. Concluding comments propose processes for more efficient development of new TB therapies.
Keywords: Tuberculosis (TB) drug development, pipeline, fluoroquinolones, nitroimidazoles, rifamycins, clinical trials
Infectious Disorders - Drug Targets
Title: Challenges Associated with Current and Future TB Treatment
Volume: 7 Issue: 2
Author(s): M. Laurenzi, A. Ginsberg and M. Spigelman
Affiliation:
Keywords: Tuberculosis (TB) drug development, pipeline, fluoroquinolones, nitroimidazoles, rifamycins, clinical trials
Abstract: Current tuberculosis (TB) treatment is based on a combination of drugs that were developed mostly in the central decades of the last century. Cure rates are high for drug sensitive strains of Mycobacterium tuberculosis (M. tb) when the recommended complex and lengthy treatment protocols are adhered to. However the difficulty in correctly prescribing and adhering to these protocols, the emergence of M. tb strains resistant to multiple drugs, and drug-drug interactions that interfere with optimal treatment of HIV and TB coinfected patients have generated a pressing need for improved TB therapies. Together with the ominous global burden of TB, these shortcomings of current treatment have contributed to a renewed interest in the development of improved drugs and protocols for the treatment of tuberculosis. This article highlights hurdles related to the optimized use of existing drugs and challenges related to the development of novel, improved products, focusing in particular on aspects inherent in TB drug clinical development. Concluding comments propose processes for more efficient development of new TB therapies.
Export Options
About this article
Cite this article as:
M. Laurenzi , A. Ginsberg and M. Spigelman , Challenges Associated with Current and Future TB Treatment, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001817
DOI https://dx.doi.org/10.2174/187152607781001817 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Infectious Disorders - Drug Targets Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry In Search of Drug Targets for Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Reaction of Some Substituted 3-Aryl-4-formylsydnones with Tetra-Oacetyl- β-D-galactopyranosyl)thiosemicarbazide
Letters in Organic Chemistry Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Progress in Structure-Based Design of EGFR Inhibitors
Current Drug Targets Architecture and Conservation of the Bacterial DNA Replication Machinery, an Underexploited Drug Target
Current Drug Targets Common Variants in Toll-Like Receptor 4 Confer Susceptibility to Alzheimer’s Disease in a Han Chinese Population
Current Alzheimer Research Isoprenoid Biosynthesis of the Apicoplast as Drug Target
Current Drug Targets Is COVID-19 a Systemic Disease?
Coronaviruses QSAR Multi-Target in Drug Discovery: A Review
Current Computer-Aided Drug Design Computational Medicinal Chemistry for Rational Drug Design: Identification of Novel Chemical Structures with Potential Anti-Tuberculosis Activity
Current Topics in Medicinal Chemistry Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Management of Spondyloarthropathy in Asian Countries
Current Rheumatology Reviews Lipid-based Nanocarriers Loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges
Current Drug Targets Analysis of DNA Microarray Data
Current Topics in Medicinal Chemistry Tuberculosis: Current Status, Diagnosis, Treatment and Development of Novel Vaccines
Current Pharmaceutical Biotechnology Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
Current Respiratory Medicine Reviews